![]() Investors can indirectly invest in these stocks by investing in IHI, which also holds stocks like Stryker (SYK) and Waters (WAT), which gave returns of 0.78% and -0.27%, respectively. ![]() BABY has a weight of 0.45% in IHI’s portfolio. They fit comfortably around the baby’s ears and help to reduce the disruptive noise levels associated withspecial patient care procedures and transport. MiniMuffs Neonatal Noise Attenuators are designed to protect the sensitive ears of premature babies. With its current price, the stock’s trailing-12-month price-to-equity was at 33.7x, and the price-to-book value stood at 3.5x. OEM: 040341MINIMUFF ASSEMBLY,36 PR by Natus Medical. The stock went up on good trading volumes of ~183,000 shares as against the five-day average trading volume of ~205,000 shares per day. ![]() The stock is trading below its 20-day, 50-day, and 100-day moving averages. Natus (BABY) gained 1.9% and closed at $39.90. MASI has a weight of 0.59% in IHI’s portfolio. MASI’s RSI (relative strength index) stood at 50, indicating that the stock is neither overbought nor oversold. MASI closed at $40.14 and was trading above its 100-day moving average. The stock has been on the upward trend since Masimo PVI was evaluated for its ability to help clinicians assess fluid responsiveness. To read this article on click here.Masimo (MASI) rose 1.4%. INFINITY PHARMA (INFI): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report Click to get this free reportĪCCURAY INC (ARAY): Free Stock Analysis ReportĪBIOMED INC (ABMD): Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. All the stocks sport a Zacks Rank #1 (Strong Buy). Management expects full year 2016 adjusted EPS in the band of $1.84–$1.88, while revenues are projected in the band of $445–$455 million.Ĭurrently, Natus Medical carries a Zacks Rank #3 (Hold).īetter-ranked stocks in the medical sector are Infinity Pharmaceuticals INFI, Abiomed ABMD and Accuray ARAY. For the first quarter of 2016, the company expects revenues in the range of $96.5–$97.5 million and adjusted EPS of 34–35 cents. Natus Medical reiterated the revenue and earnings guidance, provided on Jan 11. Revenues generated from Natus Medical’s service business initiatives, Peloton, GND and NicView were impressive.Īdjusted gross margin expanded 150 basis points (bps) on a year-over-year basis to 63.9%.Īdjusted operating margin expanded 130 bps on a year-over-year basis to 20.3%, on the back of higher revenues and an improving gross margin. continue to be sluggish due to unfavorable foreign exchange rate and economic uncertainties. The growth in revenues has been primarily achieved through entry into new markets and successful integration of previously completed acquisitions.ĭomestic Newborn Care and Neurodiagnostic businesses were particularly impressive, thanks to the efficiency of Natus Medical’s domestic sales organizations. ![]() Revenues from the neurology market increased 2.1% to $63 million, whereas revenues from the newborn care market improved 14.6% to $37 million. The upside may be attributed to improved performance in neurology and newborn care markets. Revenues increased 6.3% year over year to almost $100 million and were in line with the Zacks Consensus Estimate. Adjusted EPS surged 27.5% on a year-over-year basis and also surpassed the Zacks Consensus Estimate by a nickel. BABY reported adjusted earnings per share (EPS) of 51 cents in the fourth quarter of 2015. Provider of newborn care and neurology healthcare products, Natus Medical Inc.
0 Comments
Leave a Reply. |